Merbah Mélanie, Onkar Sayali, Grivel Jean-Charles, Vanpouille Christophe, Biancotto Angélique, Bonar Lydia, Sanders-Buell Eric, Kijak Gustavo, Michael Nelson, Robb Merlin, Kim Jerome H, Tovanabutra Sodsai, Chenine Agnès-Laurence
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, MD, USA.
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Program of Physical Biology, National Institutes of Health, MD, USA.
J Virol Methods. 2016 Apr;230:45-52. doi: 10.1016/j.jviromet.2016.01.009. Epub 2016 Jan 22.
The prevailing method to assess HIV-1 replication and infectivity is to measure the production of p24 Gag protein by enzyme-linked immunosorbent assay (ELISA). Since fluorescent bead-based technologies offer a broader dynamic range and higher sensitivity, this study describes a p24 capture Luminex assay capable of detecting HIV-1 subtypes A-D, circulating recombinant forms (CRF) CRF01_AE and CRF02_AG, which together are responsible for over 90% of HIV-1 infections worldwide. The success of the assay lies in the identification and selection of a cross-reactive capture antibody (clone 183-H12-5C). Fifty-six isolates that belonged to six HIV-1 subtypes and CRFs were successfully detected with p-values below 0.021; limits of detection ranging from 3.7 to 3 × 104 pg/ml. The intra- and inter-assay variation gave coefficient of variations below 6 and 14%, respectively. The 183-bead Luminex assay also displayed higher sensitivity of 91% and 98% compared to commercial p24 ELISA and a previously described Luminex assay. The p24 concentrations measured by the 183-bead Luminex assay showed a significant correlation (R=0.92, p<0.0001) with the data obtained from quantitative real time PCR. This newly developed p24 assay leverages the advantages of the Luminex platform, which include smaller sample volume and simultaneous detection of up to 500 analytes in a single sample, and delivers a valuable tool for the field.
评估HIV-1复制和感染性的常用方法是通过酶联免疫吸附测定(ELISA)来测量p24 Gag蛋白的产生。由于基于荧光微球的技术具有更宽的动态范围和更高的灵敏度,本研究描述了一种能够检测HIV-1 A-D亚型、循环重组型(CRF)CRF01_AE和CRF02_AG的p24捕获Luminex测定法,这些亚型和重组型共同导致了全球超过90%的HIV-1感染。该测定法的成功在于鉴定和选择了一种交叉反应捕获抗体(克隆183-H12-5C)。56株属于6种HIV-1亚型和CRF的分离株被成功检测,p值低于0.021;检测限范围为3.7至3×104 pg/ml。测定内和测定间变异的变异系数分别低于6%和14%。与商业p24 ELISA和先前描述过的Luminex测定法相比,183微球Luminex测定法还显示出更高的灵敏度,分别为91%和98%。通过183微球Luminex测定法测得 的p24浓度与定量实时PCR获得的数据显示出显著相关性(R = 0.92,p < 0.0001)。这种新开发的p24测定法利用了Luminex平台的优势,包括更小的样本体积和在单个样本中同时检测多达500种分析物,并为该领域提供了一种有价值的工具。